Chesapeake Genomic Systems, LLC

Chesapeake Genomic Systems, LLC is a for-profit organization registered in SAM.gov, located in Halethorpe, Maryland, that specializes in advanced biotechnology research and development. The company focuses on innovative genomic and synthetic biology technologies, with a particular emphasis on developing novel DNA production methods for gene therapy and research applications. Its registration in the federal system is active through June 24, 2026, indicating its ongoing commitment to providing specialized scientific services to federal research agencies.

The company has been awarded multiple project grants from the National Institute of General Medical Sciences (NIGMS), focusing on cutting-edge DNA technology development. These grants include research into synthetic circular supercoiled DNA (scsDNA) production, vectorless supercoiled DNA systems, membrane protein production techniques, and advanced DNA assembly methodologies. Specifically, their recent projects have concentrated on developing bacteria-free technologies for generating large DNA molecules, optimizing DNA assembly techniques like Cyclic Heteroduplex Thermostable Ligation Assembly (CHTLA), and creating innovative approaches to improve gene therapy vector production. Their research aims to address critical bottlenecks in viral gene therapy production workflows, with projects targeting the development of scalable, synthetic DNA production methods that offer safety and efficiency advantages over traditional bacterial plasmid-based approaches. The research spans comprehensive areas including DNA topology, in vitro assembly of large DNA fragments, and novel platforms for generating synthetic genomic constructs.